The United States oral mucositis market was valued at USD 256.74 Million in 2025 and is expected to grow at a CAGR of 6.80%, reaching USD 495.69 Million by 2035. The market growth is influenced by a strong presence of oncology centers and high awareness of supportive cancer therapies. Continuous development of mucosal protectants and novel drug delivery systems is advancing patient recovery. Moreover, robust reimbursement frameworks and increased clinical collaborations with research institutions are promoting steady expansion through the forecast period.
Base Year
Historical Period
Forecast Period
The increasing incidence of cancer, with an estimated 2,041,910 new cases expected in the United States in 2025, is significantly driving the demand for oral mucositis treatments, thereby boosting market growth.
In February 2023, Galera Therapeutics received an FDA priority review for avasopasem manganese to treat radiotherapy-induced severe oral mucositis in head and neck cancer patients, a milestone expected to significantly drive the market growth.
One of the major market trends include the adoption of oral cryotherapy devices to manage chemotherapy-induced oral mucositis. For instance, in September 2024, Sanara MedTech and InfuSystem partnered to distribute ChemoMouthpiece’s FDA-cleared device across U.S. cancer centers, supporting market growth.
Compound Annual Growth Rate
6.8%
Value in USD Million
2026-2035
*this image is indicative*
Oral mucositis often emerges during aggressive cancer treatments, posing significant challenges to patient care and recovery. The market in the United States was valued at USD 256.74 Million in 2025, and is witnessing a strong growth, driven by a high prevalence of oncology cases, extensive clinical research, and continuous innovation in topical and biological therapies. Enhanced awareness among healthcare providers, integration of laser-based healing technologies, and supportive reimbursement frameworks are contributing to the market’s expansion and improving overall treatment efficacy for affected patients.
Rising Incidence of Oral Mucositis to Drive Market Growth in the United States
The increasing prevalence of oral mucositis among cancer patients undergoing chemotherapy and radiation therapy is a key growth driver in the United States market. In September 2024, Sanara MedTech Inc. reported that an estimated 500,000 to 1,000,000 patients experience oral mucositis in the United States annually. This rising patient base has accelerated the demand for effective therapeutic solutions, including advanced topical formulations and mucosal protectants. The growing focus on improving patient comfort and treatment outcomes is expected to significantly enhance the expansion of the market in the coming years.
Some of the key trends in the market include an increasing emphasis on cancer supportive care and significant advancements in drug development.
Rising Focus on Cancer Supportive Care to Boost the Market Landscape
The growing emphasis on effective cancer supportive care therapies is a key trend shaping the United States market. For example, in October 2024, Jaguar Health launched the FDA-approved prescription product Gelclair®, designed to manage pain and promote healing in oral mucositis patients undergoing chemotherapy or radiotherapy. This innovation reflects increasing awareness of the need for safe, fast-acting treatments that improve patients’ quality of life and treatment adherence. Such advancements are expected to significantly enhance market growth in the coming years.
Advancing Drug Development to Elevate the United States Oral Mucositis Market Value
The market is witnessing a growing focus on innovative therapies for chemotherapy-induced oral mucositis. In July 2024, Supportive Therapeutics’ investigational drug ST-617, developed in Cambridge, Massachusetts, entered Phase I clinical trials for chemoradiation-induced oral mucositis. The drug’s strong phase transition success rate highlights rising innovation and research investment in reducing cancer therapy side effects. This increasing clinical activity and development pipeline is expected to substantially enhance the market’s growth potential in the coming years.
Hospitals and Clinics Expected to Dominate the Market Share by End User
The market is segmented by end user into hospitals and clinics, ambulatory surgical centers (ASCs), and others. Among these, hospitals and clinics are expected to lead the market due to their advanced infrastructure, availability of specialized healthcare professionals, and higher patient inflow for oncology and radiation treatments. Their capacity to provide comprehensive care, including diagnosis, prevention, and management of mucositis, positions them as the primary setting for effective treatment delivery.
The key features of the market report comprise funding and investment analysis, clinical trials and pipeline analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Amgen Inc., based in California, holds a significant market position with its FDA-approved flagship therapy, Kepivance (palifermin). As the first treatment developed to reduce severe oral mucositis in bone marrow transplant patients, it marks a major advancement in cancer supportive care. Through continuous research and clinical validation, Amgen reinforces its leadership in advancing biologic therapies that improve treatment tolerability.
Innovation Pharmaceuticals is a key player in the United States oral mucositis market. The company presented Phase 2 data for Brilacidin-OM demonstrating substantial reductions in severe oral mucositis among head and neck cancer patients receiving aggressive chemotherapy. Company leadership characterized the outcomes as clinically meaningful and supportive of late-stage development. With Fast Track status from the U.S. Food and Drug Administration and ongoing analysis of the clinical study report, Innovation plans to refine trial design and explore market access considerations to advance Brilacidin-OM toward potential approval.
Galera Therapeutics Inc., headquartered in Pennsylvania, is contributing significantly to improving supportive cancer therapies within the United States. Its core focus lies in developing avasopasem manganese, a novel therapy targeting radiation-related oral mucositis in head and neck cancer patients. By emphasizing scientific rigor and clinical innovation, the company seeks to address an unmet need in oncology care and strengthen its position as a key developer of next-generation radiotherapy protection solutions.
Soligenix Inc., headquartered in the United States, remains actively engaged in developing therapies for conditions like oral mucositis, which significantly affect patients receiving chemoradiation. Through ongoing research and late-stage clinical programs, the company aims to fill critical gaps in supportive oncology care. Its efforts demonstrate a strong alignment with healthcare priorities focused on improving the quality of life and ensuring continuity of cancer treatment for affected patients.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Pfizer Inc., Monopar Therapeutics Inc., Oragenics Inc., Jaguar Health Inc., EpicentRx Inc., and Enzychem Lifesciences.
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Class
Market Breakup by End User
Market Breakup by Distribution Channel
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Class |
|
| Breakup by End User |
|
| Breakup by Distribution Channel |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share